64Cu-GRIP B PET Imaging for Genitourinary Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial uses a special imaging technique to help see how well the immune system is fighting advanced GU cancers. It targets patients with specific types of advanced cancers and works by highlighting areas where immune cells are attacking cancer cells. This can help predict how well treatments are working.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Is 64Cu-GRIP B PET Imaging safe for humans?
Preclinical studies on similar 64Cu-labeled compounds for imaging prostate cancer have shown favorable biodistribution and stability, with no significant safety concerns reported in animal models. However, specific human safety data for 64Cu-GRIP B is not available, so further clinical evaluation is needed to confirm its safety in humans.12345
How does the 64Cu-GRIP B PET Imaging treatment differ from other treatments for genitourinary cancer?
64Cu-GRIP B PET Imaging is unique because it uses a radiotracer to noninvasively visualize and track immune cell activity, specifically targeting granzyme B, which is released by immune cells during an immune response. This approach allows for early assessment of how well a patient's immune system is responding to cancer treatment, potentially improving the precision of immunotherapy strategies.678910
What data supports the effectiveness of the drug 64Cu-GRIP B for genitourinary cancer?
Research on similar treatments shows that PET imaging using granzyme B-targeted radiotracers can effectively predict tumor responses to immunotherapy in various cancers. This suggests that 64Cu-GRIP B, which targets granzyme B, might also help in assessing and potentially improving treatment responses in genitourinary cancer.46789
Who Is on the Research Team?
Rahul Aggarwal, MD
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
This trial is for adults with advanced genitourinary cancers, such as kidney and urethral cancer. Participants must be over 18, not pregnant or breastfeeding, willing to use contraception, and have a good performance status (able to carry out daily activities). They should have adequate organ function and specific types of metastatic cancer confirmed by tests.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline PET Imaging
All participants receive 64Cu-GRIP B PET imaging at baseline to assess initial uptake
Follow-up Imaging
Participants in Cohorts B and C undergo additional PET scans at 8 weeks and at disease progression
Long-term Follow-up
Participants are monitored for safety and effectiveness, with follow-up for up to 2 years
What Are the Treatments Tested in This Trial?
Interventions
- 64Cu-GRIP B
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rahul Aggarwal
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
U.S. Army Medical Research Acquisition Activity
Collaborator